Gilead is aiming to enter the market for hepatitis C treatment Vosevi, which has failed to designate an orphan drug in Korea.

According to related industries, Gilead Science Korea is in the process of marketing approval of the three-drug combination Vosevi (Sofosbuvir + Velpatasvir + Voxilaprevir) along with the hepatitis C combination drug Epclusa (Sofosbuvir / Velpatasvir).

Vosevi's designation as an orphan drug was canceled because it did not meet the criteria for orphan drug designation in 2018. This drug, like AbbVie's Maviret (Glecaprevir + Pibrentasvir), relieved the discomfort of using Ribavirin in combination with a pangenic hepatitis C treatment, or the duration of treatment.

Eo, Yun-Ho(unkindfish@dailypharm.com)